Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(Rheumatoid Arthritis)
145,233 results
  • Real-world outcomes among patients with early rapidly progressive rheumatoid arthritis. [Journal Article]
    Am J Manag Care 2019; 25(10):e288-e295Klink AJ, Curtice TG, … Feinberg BA
  • CONCLUSIONS: Adjusting for disease severity, patients with eRPRA who were treated with first-line abatacept were less likely to have hospitalizations, ED visits, and MRI use during the first 6 months of bDMARD treatment and more likely to achieve low disease activity within 100 days of bDMARD start compared with those who received a first-line TNF inhibitor.
  • Knee and hip osteoarthritis as predictors of premature death: a review of the evidence. [Review]
    Clin Exp Rheumatol 2019 Sep-Oct; 37 Suppl 120(5):24-30Cleveland RJ, Nelson AE, Callahan LF
  • Rheumatic and musculoskeletal diseases (RMDs) are common, with osteoarthritis (OA) being the most prevalent. RMDs, including OA, are associated with significant pain and functional limitations, as well as mortality rates up to 1.6-fold higher than in the general population. Most studies of OA and mortality have focused on knee and hip OA. Some, but not all, of these studies suggest an increased r…
  • Ulcerative Colitis and Familial Mediterranean Fever: Can Anakinra Treat Both? [Case Reports]
    ACG Case Rep J 2019; 6(7):e00143Kaly L, Rozenbaum M, … Rosner I
  • Anakinra is a biological drug used in rheumatoid arthritis and several autoinflammatory diseases. Its main side effects are injection site reactions and increased infection rate. We present a 28-year-old man with familial Mediterranean fever, whose disease went into remission on anakinra, with concomitant flare of his ulcerative colitis.
New Search Next